Department of Surgery, University of California, San Francisco, California, USA.
Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio, USA.
mSystems. 2024 Nov 19;9(11):e0123724. doi: 10.1128/msystems.01237-24. Epub 2024 Oct 29.
This study characterized and compared the fecal and oral microbiota from women with early-stage breast cancer (BC), women with ductal carcinoma (DCIS), and healthy women. Fecal and oral samples were collected from newly diagnosed patients prior to any therapy and characterized using 16S rRNA sequencing. Measures of gut microbial alpha diversity were significantly lower in the BC vs healthy cohort. Beta diversity differed significantly between the BC or DCIS and healthy groups, and several differentially abundant taxa were identified. Clustering (non-negative matrix factorization) of the gut microbiota identified five bacterial guilds dominated by , Enterobacteriaceae, , Clostridiales, or . The and Enterobacteriaceae guilds were significantly more abundant in the BC cohort compared to healthy controls, whereas the Clostridiales guild was more abundant in the healthy group. Finally, prediction of functional pathways identified 23 pathways that differed between the BC and healthy gut microbiota including lipopolysaccharide biosynthesis, glycan biosynthesis and metabolism, lipid metabolism, and sphingolipid metabolism. In contrast to the gut microbiomes, there were no significant differences in alpha or beta diversity in the oral microbiomes, and very few differentially abundant taxa were observed. Non-negative matrix factorization analysis of the oral microbiota samples identified seven guilds dominated by , , Gemellaceae, , , , and ; however, none of these guilds were differentially associated with the different cohorts. Our results suggest that alterations in the gut microbiota may provide the basis for interventions targeting the gut microbiome to improve treatment outcomes and long-term prognosis.
Emerging evidence suggests that the gut microbiota may play a role in breast cancer. Few studies have evaluated both the gut and oral microbiomes in women with breast cancer (BC), and none have characterized these microbiomes in women with ductal carcinoma (DCIS). We surveyed the gut and oral microbiomes from women with BC or DCIS and healthy women and identified compositional and functional features of the gut microbiota that differed between these cohorts. In contrast, very few differential features were identified in the oral microbiota. Understanding the role of gut bacteria in BC and DCIS may open up new opportunities for the development of novel markers for early detection (or markers of susceptibility) as well as new strategies for prevention and/or treatment.
本研究对早期乳腺癌(BC)、导管癌(DCIS)患者和健康女性的粪便和口腔微生物群进行了特征描述和比较。在接受任何治疗之前,从新诊断的患者中采集粪便和口腔样本,并使用 16S rRNA 测序进行特征描述。与健康队列相比,BC 组的肠道微生物 alpha 多样性显著降低。BC 或 DCIS 与健康组之间的 beta 多样性存在显著差异,并且确定了几个差异丰富的分类群。肠道微生物群的聚类(非负矩阵分解)鉴定了五个细菌群,分别由 、肠杆菌科、梭状芽孢杆菌或 主导。与健康对照组相比,BC 队列中 和肠杆菌科菌群明显更丰富,而健康组中梭状芽孢杆菌菌群更丰富。最后,对功能途径的预测确定了 23 条在 BC 和健康肠道微生物群中不同的途径,包括脂多糖生物合成、聚糖生物合成和代谢、脂质代谢和鞘脂代谢。与肠道微生物群不同,口腔微生物群的 alpha 或 beta 多样性没有显著差异,观察到的差异丰富的分类群很少。口腔微生物样本的非负矩阵分解分析确定了七个由 、 、Gemellaceae、 、 、 和 主导的菌群;然而,这些菌群都与不同的队列没有差异相关。我们的研究结果表明,肠道微生物群的改变可能为靶向肠道微生物群的干预提供基础,以改善治疗结果和长期预后。
越来越多的证据表明,肠道微生物群可能在乳腺癌中发挥作用。很少有研究评估乳腺癌女性的肠道和口腔微生物群,也没有研究描述导管癌(DCIS)女性的这些微生物群。我们调查了 BC 或 DCIS 患者和健康女性的肠道和口腔微生物群,并确定了这些队列之间肠道微生物群的组成和功能特征。相比之下,口腔微生物群中很少有差异特征被识别。了解肠道细菌在 BC 和 DCIS 中的作用可能为开发新的早期检测标志物(或易感性标志物)以及预防和/或治疗的新策略开辟新的机会。